Gene · 5588
PRKCQ: protein kinase C theta
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PRKCQ: protein kinase C theta. Genes, record 5588. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5588
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q04759 | Protein kinase C theta type | 706 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents91
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59731 | Q04759 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 259 | Q04759 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1740 | Q04759 | Espacenet |
| JP 2025524002 A | 2025-07-25 | 6 | Q04759 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 259 | Q04759 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1740 | Q04759 | Espacenet |
| KR 1020250039465 A | 2025-03-20 | 6 | Q04759 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 34066 | Q04759 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 34066 | Q04759 | Espacenet |
| JP 2024023699 A | 2024-02-21 | 6 | Q04759 | Espacenet |
1 to 10 of 91
See all 91 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CEP-2563 | CHEMBL6069183 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
| CEP-2563 DIHYDROCHLORIDE | CHEMBL6067987 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
| GSK-690693 | CHEMBL494089 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
| MIDOSTAURIN | CHEMBL608533 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
| SOTRASTAURIN | CHEMBL565612 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
| UCN-01 | CHEMBL574737 | Protein kinase C (PKC) inhibitor | INHIBITOR | ChEMBL |
Trials71
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07572695 | MIDOSTAURIN | ClinicalTrials.gov | ||
| NCT06313437 | MIDOSTAURIN | PHASE1 | ClinicalTrials.gov | |
| NCT05219266 | MIDOSTAURIN | ClinicalTrials.gov | ||
| NCT04982354 | MIDOSTAURIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04496999 | MIDOSTAURIN | PHASE1 | ClinicalTrials.gov | |
| NCT04385290 | MIDOSTAURIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04174612 | MIDOSTAURIN | PHASE3 | ClinicalTrials.gov | |
| NCT04097470 | MIDOSTAURIN | PHASE2 | ClinicalTrials.gov | |
| NCT04075747 | MIDOSTAURIN | PHASE1 | ClinicalTrials.gov | |
| NCT04027309 | MIDOSTAURIN | PHASE3 | ClinicalTrials.gov |
1 to 10 of 71
See all 71 trialsNIH grants1,481
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PRKCQ papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30DK045735 | Yale Diabetes Research Center | 8 | 2025 |
| P01CA065493 | Off-the-Shelf Immune Effector Cells for Hematological Malignancies | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 5 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 4 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 4 | 2025 |
| ZIABC011470 | Development of Natural Product Leads as Anticancer Therapeutics | 4 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,481Source NIH's project files
See all 1,481 nih grantsPapers1,848
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Protein Kinase C-fused blue naevi with gene rearrangements involving PRKCD, PRKCQ, and PRKCG: expanding the genetic spectrum of an uncommon entity. | Pathology | 2026 | 42827077 | PubTator, text mining | PubMed |
| SUMOylation-Driven Subtype Heterogeneity and Prognostic Biomarkers in Renal Cell Carcinoma. | Curr Issues Mol Biol | 2026 | 42651750 | PubTator, text mining | PubMed |
Identification and quantification of putative active constituents of huangqin decoction for ulcerative colitis treatment through the integration of chemical profiling, network pharmacology, and bioinformatics. | Front Chem | 2026 | 42602043 | PubTator, text mining | PubMed |
| Integrative network pharmacology, transcriptomics, and molecular docking identify candidate Centella asiatica constituents and targets in neurodegenerative diseases. | PLoS One | 2026 | 42536688 | PubTator, text mining | PubMed |
| Uncovering Genetic Drivers of MASLD in South Asia: A Whole-Exome Sequencing Study in Pakistan. | J Coll Physicians Surg Pak | 2026 | 42219829 | PubTator, text mining | PubMed |
| PKCθ: from T cell kinase to immunometabolic integrator. | Trends Pharmacol Sci | 2026 | 42103538 | PubTator, text mining | PubMed |
| Identification of PANoptosis-related biomarkers in spinal cord injury (SCI) through multi-omics analysis and machine learning. | Int J Neurosci | 2026 | 42037113 | PubTator, text mining | PubMed |
| Protein kinase C theta: evolution, regulation, and function. | Biochem J | 2026 | 41979916 | PubTator, text mining | PubMed |
| Regulatory T cells in axial spondyloarthritis. | Commun Biol | 2026 | 41917236 | PubTator, text mining | PubMed |
| Associations of non-HLA gene polymorphisms with celiac disease in India. | Sci Rep | 2026 | 41882060 | PubTator, text mining | PubMed |
1 to 10 of 1,848
See all 1,848 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5588
GET https://conductscience.org/api/genes/v1/5588/patents?page=2